Early application of intravenous immunoglobulin may reduce the probability of coronary artery disease in patients with Kawasaki disease. However, as immunoglobulin is a blood product, many parents are concerned about the safety of the product after infusion, such as the possibility of contracting blood-borne infectious diseases such as AIDS, syphilis and hepatitis.
In fact, immunoglobulins produced by regular manufacturers have undergone strict sterilization tests and it is extremely rare for germs to be transmitted. In addition, the late stage coronary artery lesions in Kawasaki disease seriously endanger the long-term cardiac health of the child, and the application of immunoglobulin is also necessary.